The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
Please sign up for SocialPicks site access - it's free!

Celgene (CELG): Play offense and defense with biotech

 Jun 22, 2009 06:40 PM UTC
Return Risk
+3.28% MID
Tracked Blogger
Symbol Sentiment Start Return Closed
CELG Positive 06/22/09 +14.52% 08/19/09

Graphic_arrow1 Via BloggingStocks:  

Filed under: Newsletters, Stocks to Buy

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.


In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."


"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.


"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments



Add to digg
Add to del.icio.us
Add to Google
Add to StumbleUpon
Add to Facebook
Add to Reddit
Add to Technorati



 Graphic_website1 Read the rest of original post »



Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch